Gentris Corp. has opened a new genomic biomarker testing and biorepository services lab in Shanghai, China. Gentris Shanghai will provide GCLP-compliant testing and biobanking services for global pharmaceutical clients under international standards.
"The launch of Gentris Shanghai is a tremendous milestone for our company," said Dr. Amelia Wall Warner, Gentris president and chief executive officer. "Gentris is creating an international quality, global organization capable of providing genomic biomarker testing and biobanking services for clinical trials. In addition to commercial services, we are building collaborations with top Chinese research organizations, universities, and companies to accelerate drug development and innovation."
Initial services will include biobanking and nucleic acid prep, with genotyping and gene expression services to launch in 2014 with phased implementation based on demand.